Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry

. In the VICTORIA trial, vericiguat reduced the risk of cardiovascular mortality and heart failure (HF) hospitalization among patients with heart failure with reduced ejection fraction (HFrEF) and a recent worsening heart failure event (WHFE). The representativeness of VICTORIA population to patients with WHFE in clinical practice is unknown.

Source: Journal of Cardiac Failure - July 13, 2021 Category: Cardiology Authors: Javed Butler, Laurence M. Djatche, Dominik Lautsch, Lingfeng Yang, Mahesh J. Patel, Robert J. Mentz Source Type: research